Bluewater Bio Appoints Dr. Piers Clark to Board

Bluewater Bio, Ltd., a wastewater company, announced the appointment of non-executive Director Dr. Piers Clark, a technical and industry expert within the water and energy sectors. This board appointment comes at a time when Bluewater Bio is experiencing the global roll-out of its HYBACS (Hybrid Bacillus Activated Sludge) technology, driven by increased legislative and economic demand for water management and reuse.

Clark brings to Bluewater Bio more than 20 years’ experience in the water, waste and utilities industries, since joining North West Water as a Research Scientist in 1994. His most recent position has been as interim asset director with Thames Water, one of the U.K.'s largest water and wastewater services companies. Prior to this, Clark served as managing director for utilities at Mouchel, Ltd., and management board member of parent group Mouchel plc, an engineering consultancy firm. During his five years at Mouchel, where he led a team of around 3,000 staff across the water, energy, environment and rail sectors, Clark saw turnover treble and profits increase. Primary achievements include the coordination of key international acquisitions and driving innovation across the utilities sector through his leading role in the Mouchel-sponsored industry-wide Technology Approvals Group.

Clark currently holds a non-executive director position at Empire Water in California and is also active within the sector’s financial community, where he advises the Emerald Cleantech fund. He has published over 30 technical papers and several patent applications.

“I am delighted to have joined the board of Bluewater Bio,” Clark said. “This company has tremendous potential to improve wastewater treatment worldwide with its highly successful HYBACS technology. As a non-executive director, I believe that my experience in the sector can readily be leveraged by the team at Bluewater Bio throughout this exciting stage in their development and beyond.”

Source: Bluewater Bio